Latest Conference Articles

September 16th 2018, 8:19pm

International Liver Cancer Association Annual Conference

Masatoshi Kudo, MD, PhD, professor and chairman, Department of Gastroenterology and Hepatology, Kindai University, Osaka, Japan, discusses the results of a cost-effectiveness analysis of lenvatinib versus sorafenib in unresectable hepatocellular carcinoma in Japan.

September 16th 2018, 8:06pm

International Liver Cancer Association Annual Conference

Richard Finn, MD, professor of clinical medicine in the Division of Hematology and Oncology, director of the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at the University of California, Los Angeles, discusses the role lenvatinib (Lenvima) in the treatment paradigm for advanced hepatocellular carcinoma.

September 16th 2018, 7:57pm

International Liver Cancer Association Annual Conference

Riccardo Lencioni, MD, professor in the department of radiology at the University of Pisa School of Medicine in Pisa, Italy, discusses how response to hepatocellular carcinoma (HCC) treatment can be best assessed in patients.

September 16th 2018, 7:48pm

International Liver Cancer Association Annual Conference

Bruno Sangro, MD, discussed the current landscape for systemic therapies, new directions with immunotherapy, and the need for greater research into combination therapies for patients with hepatocellular carcinoma.

September 16th 2018, 7:29pm

International Liver Cancer Association Annual Conference

Regorafenib maintained a prolonged overall survival benefit as second-line therapy for patients with advanced hepatocellular carcinoma in a 2-year updated analysis of key findings from the pivotal RESORCE trial.

September 16th 2018, 3:11am

International Liver Cancer Association Annual Conference

The positive outcomes that lenvatinib demonstrated as first-line therapy for patients with hepatocellular carcinoma are confirmed in an independent assessment conducted as part of the pivotal, international phase III REFLECT trial.

September 15th 2018, 9:49pm

International Liver Cancer Association Annual Conference

Ann-Lii Cheng, MD, PhD, distinguished professor and director of the cancer center of National Taiwan University, discusses the challenges that tumor heterogeneity in hepatocellular carcinoma (HCC) pose for clinical trials.

September 15th 2018, 9:34pm

International Liver Cancer Association Annual Conference

Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, describes what he sees as key areas of research into the treatment of hepatocellular carcinoma as therapy moves beyond existing drugs and into novel approaches.

September 15th 2018, 8:52pm

International Liver Cancer Association Annual Conference

Morris Sherman, MD, PhD, shared his insight on the news and discussions coming out of this year’s meeting, the surge of immunotherapy and targeted therapy research, optimal sequencing approaches, and the challenges that remain in treating patients with hepatocellular carcinoma.

September 15th 2018, 8:01pm

International Liver Cancer Association Annual Conference

Cabozantinib improved survival as second-line therapy for patients with hepatocellular carcinoma who also had a history of hepatitis B virus infection.

September 15th 2018, 12:59am

International Liver Cancer Association Annual Conference

The combination of atezolizumab and bevacizumab demonstrated strong signals of efficacy with a tolerable safety profile as first-line therapy for patients with unresectable or metastatic hepatocellular carcinoma.

September 15th 2018, 12:41am

International Liver Cancer Association Annual Conference

Augusto Villanueva, MD, PhD, assistant professor, Icahn School of Medicine, discusses the potential of liquid biopsy to improve treatment for patients with hepatocellular carcinoma (HCC).

September 15th 2018, 12:40am

International Liver Cancer Association Annual Conference

Josep M. Llovet, MD, PhD, Icahn School of Medicine, discusses the potential for biomarkers to improve the treatment of hepatocellular carcinoma (HCC).

September 14th 2018, 11:37pm

International Liver Cancer Association Annual Conference

The rapid development of novel therapies for patients with unresectable hepatocellular carcinoma has dramatically expanded the options for systemic treatments over the past 2 years, creating the need for new sequencing strategies.

September 14th 2018, 4:59pm

International Liver Cancer Association Annual Conference

Updates to the European Association for the Study of the Liver clinical guidelines introduce more opportunities for individual patient management of hepatocellular carcinoma.

July 29th 2018, 4:19am

International Lung Cancer Congress

As the checkpoint inhibitors move into the frontline setting for patients with non–small cell lung cancer, the focus has been placed on the duration of therapy and what to do in the second-line setting following progression.

July 29th 2018, 4:07am

International Lung Cancer Congress

Recent positive clinical trial data have provided the oncology community with several sequencing strategies for patients with EGFR-mutant non-small cell lung cancer.

July 29th 2018, 2:43am

International Lung Cancer Congress

RET is set to join the list of ever-expanding actionable driver mutations for non–small cell lung cancer, as there are now 3 highly effective therapies in development.

July 29th 2018, 1:20am

International Lung Cancer Congress

The use of frontline versus second-line tyrosine kinase inhibitor use is controversial in many oncogene-driven non-small cell lung cancers.

July 28th 2018, 6:47pm

International Lung Cancer Congress

Heather Wakelee, MD, associate professor of medicine (oncology) at the Stanford University Medical Center, discussed the latest therapeutic developments in EGFR-mutant non-small cell lung cancer.